Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

Notable signs and symptoms distinguishing bronchiectasis from other pulmonary disease states are discussed. This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the ...

Please provide your email address to receive an email when new articles are posted on . New endpoints from the ASPEN trial were presented at the World Bronchiectasis Conference. FDA new drug ...

Please provide your email address to receive an email when new articles are posted on . For adults with bronchiectasis, $82,545 was the highest annual health care cost observed in a systematic review.

Manage bronchiectasis effectively with these practical lifestyle tips that can help reduce flare-ups, prevent infections, and keep your lungs clear.

FIRS organizations, including the American Thoracic Society, call for improving early detection of bronchiectasis. July 1, 2025 – According to the 2022 Global Impact of Respiratory Disease Report, the ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the ...